Recurrent Adult Immunoblastic Large Cell Lymphoma Terminated Phase 1 Trials for Rituximab (DB00073)

IndicationStatusPhase
DBCOND0028500 (Recurrent Adult Immunoblastic Large Cell Lymphoma)Terminated1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02168907CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin LymphomaTreatment
NCT01045928Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin LymphomaTreatment